XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Earnings per Common Share | 12 Months Ended
--- | ---
Dec. 31, 2021
Earnings Per Share [Abstract] |
Earnings per Common Share | Earnings per Common Share: The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):
| For the Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Basic: |  |  |  |  |
Numerator: |  |  |  |  |
Income from continuing operations | $ | 517.6 |  |  | $ | 368.8 |  |  | $ | 446.4 |
Less: Net income attributable to noncontrolling interests included in continuing operations | (105.0) |  |  | (84.6) |  |  | (87.1) |
Less: Income allocated to participating securities | (1.8) |  |  | (1.0) |  |  | (1.3) |
Income from continuing operations attributable to Encompass Health common shareholders | 410.8 |  |  | 283.2 |  |  | 358.0 |
Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders | (0.4) |  |  | — |  |  | (0.6) |
Net income attributable to Encompass Health common shareholders | $ | 410.4 |  |  | $ | 283.2 |  |  | $ | 357.4 |
Denominator: |  |  |  |  |
Basic weighted average common shares outstanding | 99.0 |  |  | 98.6 |  |  | 98.0 |
Basic earnings per share attributable to Encompass Health common shareholders: |  |  |  |  |
Continuing operations | $ | 4.15 |  |  | $ | 2.87 |  |  | $ | 3.66 |
Discontinued operations | — |  |  | — |  |  | (0.01) |
Net income | $ | 4.15 |  |  | $ | 2.87 |  |  | $ | 3.65 |
Diluted: |  |  |  |  |
Numerator: |  |  |  |  |
Income from continuing operations | $ | 517.6 |  |  | $ | 368.8 |  |  | $ | 446.4 |
Less: Net income attributable to noncontrolling interests included in continuing operations | (105.0) |  |  | (84.6) |  |  | (87.1) |
Income from continuing operations attributable to Encompass Health common shareholders | 412.6 |  |  | 284.2 |  |  | 359.3 |
Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders | (0.4) |  |  | — |  |  | (0.6) |
Net income attributable to Encompass Health common shareholders | $ | 412.2 |  |  | $ | 284.2 |  |  | $ | 358.7 |
Denominator: |  |  |  |  |
Diluted weighted average common shares outstanding | 100.2 |  |  | 99.8 |  |  | 99.4 |
Diluted earnings per share attributable to Encompass Health common shareholders: |  |  |  |  |
Continuing operations | $ | 4.11 |  |  | $ | 2.85 |  |  | $ | 3.62 |
Discontinued operations | — |  |  | — |  |  | (0.01) |
Net income | $ | 4.11 |  |  | $ | 2.85 |  |  | $ | 3.61 |
The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):
| For the Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Basic weighted average common shares outstanding | 99.0 |  |  | 98.6 |  |  | 98.0 |
Restricted stock awards, dilutive stock options, and restricted stock units | 1.2 |  |  | 1.2 |  |  | 1.4 |
Diluted weighted average common shares outstanding | 100.2 |  |  | 99.8 |  |  | 99.4 |
Options to purchase approximately 0.2 million, 0.2 million, and 0.1 million shares of common stock were outstanding as of December 31, 2021, 2020, and 2019, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive. In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $200 million to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. There were no repurchases of our common stock during 2021. During 2020 and 2019, we repurchased 0.1 million and 0.8 million shares of our common stock in the open market for $6.1 million and $45.9 million, respectively. In July 2018, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.27 per share. The cash dividend of $0.27 per common share was declared and paid in each quarter through July 2019. In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.28 per share. The cash dividend of $0.28 per common share was declared and paid in each quarter through January 2022. Future dividend payments are subject to declaration by our board of directors.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration